Overview


Hypercholesterolemia is characterised by elevated levels of total cholesterol and LDL (bad) cholesterol in the blood. Total blood cholesterol levels should be between 140 and 200 mg/dL in a healthy person. Hypercholesterolemia causes cardiovascular disorders including atherosclerosis and stroke, among other things. High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, and Very low-density lipoprotein (VLDL) cholesterol make up the majority of human blood cholesterol. HDL cholesterol is regarded as the body's "healthy" cholesterol. High levels of HDL cholesterol lower the risk of heart disease, and HDL naturally eliminates cholesterol from cells by transporting it to the liver via reverse cholesterol transport. Hand LDL, on the other hand, contributes to plaque, a thick, dense deposit that clogs arteries and makes them more flexible. The medical word for this condition is atherosclerosis. Heart attacks, strokes, and peripheral arterial disorders are caused by clots that develop and obstruct constricted arteries. Increased levels of low-density lipoprotein (LDL) in the blood arteries cause familial hypercholesterolemia, a hereditary illness. People with familial hypercholesterolemia are thought to have a higher chance of having heart problems. The market for familial hypercholesterolemia treatment is predicted to grow in the next years as the rate of diagnosis and treatment adoption rises. Hypercholesterolemia is frequently the result of a combination of environmental and genetic risk factors. Due to the existence of a mutant copy of the LDL receptor gene, the genetic condition causes heterozygous familial hypercholesterolemia. The market for familial hypercholesterolemia treatment has grown as a result of the increased adoption of combination therapy and the availability of high-level manufacturing technology.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Familial Hypercholesterolemia Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Familial Hypercholesterolemia Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AbbVie Inc.
  • Aegerion Pharmaceuticals
  • Novartis AG
  • AstraZeneca Plc.
  • Merck Company
  • Pfizer Inc.
  • Sanofi S.A.
  • Amgen Inc.
  • Daiichi Sankyo Company Limited
  • Esperion Therapeutics
  • CJ Healthcare

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Indication Type

  • Heterozygous familial hypercholesterolemia
  • Homozygous familial hypercholesterolemia

By Drug

  • Statins
  • Bile-acid-binding resins
  • Cholesterol absorption inhibitors
  • Combination cholesterol absorption inhibitor and statin
  • Fibrates
  • Niacin
  • Omega-3 fatty acid supplements

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Institutional Sales
  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Retail Sales
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Familial Hypercholesterolemia Treatment Market By Indication Type, By Drug, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Familial Hypercholesterolemia Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Familial Hypercholesterolemia Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Familial Hypercholesterolemia Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Familial Hypercholesterolemia Treatment Market, By Indication Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Heterozygous familial hypercholesterolemia
        2. Homozygous familial hypercholesterolemia

  • 8.   Familial Hypercholesterolemia Treatment Market, By Drug Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Statins
        2. Bile-acid-binding resins
        3. Cholesterol absorption inhibitors
        4. Combination cholesterol absorption inhibitor and statin
        5. Fibrates
        6. Niacin
        7. Omega-3 fatty acid supplements

  • 9.   Familial Hypercholesterolemia Treatment Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Injectable

  • 10.   Familial Hypercholesterolemia Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Institutional Sales
        2. Hospitals
        3. Specialty Clinics
        4. Research Institutes
        5. Retail Sales
        6. Retail Pharmacies
        7. Online Pharmacies

  • 11.   North America Familial Hypercholesterolemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Familial Hypercholesterolemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Familial Hypercholesterolemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Familial Hypercholesterolemia Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AbbVie Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Aegerion Pharmaceuticals
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AstraZeneca Plc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Merck Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sanofi S.A.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Amgen Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Daiichi Sankyo Company Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Esperion Therapeutics
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. CJ Healthcare
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients